导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.80% | 2011/4773 |
| 近一周 | -2.64% | 2743/5462 |
| 近一月 | -5.22% | 3109/5421 |
| 近一季 | -14.50% | 4162/5209 |
| 近半年 | -4.72% | 2594/4920 |
| 近一年 | 7.54% | 1291/4366 |
| 近两年 | 68.66% | 1003/2954 |
| 近三年 | 44.18% | 639/2253 |
| 成立以来 | 156.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.08% 1642/4961 |
20.40% 1230/5312 |
- - |
- - |
| 2025 | 36.18% 957/4813 |
-0.30% 2189/3635 |
5.48% 584/4076 |
26.44% 1351/4524 |
2.41% 959/4813 |
| 2024 | 12.74% 1215/3463 |
0.49% 961/2808 |
0.57% 580/3014 |
11.58% 2500/3129 |
-0.03% 1296/3463 |
| 2023 | -11.35% 1394/2656 |
5.31% 802/2280 |
-1.25% 458/2385 |
-8.26% 1686/2515 |
-7.09% 2045/2655 |
| 2022 | -15.85% 433/2207 |
-13.64% 803/1919 |
8.72% 332/2016 |
-10.91% 463/2113 |
0.60% 1480/2208 |
| 2021 | 19.19% 197/1822 |
-2.16% 591/1255 |
16.11% 211/1330 |
1.81% 445/1466 |
3.05% 482/1822 |
| 2020 | 48.41% 186/1250 |
-4.28% 351/1028 |
21.23% 240/1067 |
14.55% 271/1164 |
11.66% 527/1184 |
| 2019 | 40.05% 261/1092 |
23.56% 551/739 |
-3.40% 389/788 |
7.92% 73/850 |
8.73% 295/918 |
| 2018 | -28.19% 436/834 |
- - |
-14.92% 503/631 |
-6.16% 391/660 |
-9.13% 131/682 |
| 2017 | 11.35% 296/714 |
- - |
- - |
- - |
- - |
| 2016 | 0.79% 99/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信精工制造指数增强 VS. 长安沪深300非周期A(740101) |